, Volume 65, Supplement 1, pp 97–104 | Cite as

Safety of Potent Gastric Acid Inhibition

  • Carlos Martín de Argila de Prados
Review Article


The proton pump inhibitors are a very effective drug group for the control of gastric acid secretion, which makes them of great use in the medical practice setting, while at the same time they represent one of the treatment groups widely used in Western European countries. These factors lead to this drug group being prescribed in all age populations, quite often in polimeticated patients and with pluripathology, and on many occasions during prolonged periods of time. All these determinant factors sometimes make the safety profile of proton pump inhibitors disputable. In this respect all of them have been shown to have little adverse events and are safe in long-term treatment. The risk of drug interactions when prescribed in association with other drugs is low and their repercussion in the medical practice setting is quite exceptional as they require few dosage adjustments in patients with severe concomitant diseases and in elderly patients. Finally, their safety is high in pregnant women and in children, although further studies in this population are required to corroborate this evidence.


Warfarin Omeprazole Proton Pump Inhibitor Lansoprazole Esomeprazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 2003. Información Terapéutica de la Seguridad Social 2004; 28: 121–4.Google Scholar
  2. 2.
    Andersson T, Cederberg C, Edvarsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79–85PubMedCrossRefGoogle Scholar
  3. 3.
    Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Ageing 2002; 19: 911–27CrossRefGoogle Scholar
  4. 4.
    Horai Y, Ishizaki T. Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Ration Drug Ther 1988; 22: 1–8Google Scholar
  5. 5.
    Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26: 753–9PubMedCrossRefGoogle Scholar
  6. 6.
    Bertilsson I. Geographic/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C 19. Clin Pharmacokinet 1995; 29: 192–209Google Scholar
  7. 7.
    Ishizaki T, Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13: 27–36PubMedCrossRefGoogle Scholar
  8. 8.
    Andersson T. Pharmacokinetics, metabolism and interac-tions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9–28PubMedCrossRefGoogle Scholar
  9. 9.
    Andersson T, Holmberg J, Rösh K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369–75PubMedCrossRefGoogle Scholar
  10. 10.
    Humphries TJ, Merrit GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13 Suppl 3: 18–26PubMedCrossRefGoogle Scholar
  11. 11.
    Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omperazole’s inhibition of diazepam metabolism. Clin Pharmacol Ther 1995; 58: 62–72PubMedCrossRefGoogle Scholar
  12. 12.
    Andersson T, Andren K, Cederberg C, et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51–4PubMedCrossRefGoogle Scholar
  13. 13.
    Li G, Klotz U. Inhibitory effect of omeprazole on the metabolism of midazolam in vitro. Arzneimittelforschung 1990; 40: 1105–7PubMedGoogle Scholar
  14. 14.
    Marti-Masso JF, Lopez de Munain A, Lopez de Dicastillo G. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Ann Pharmacother 1992; 26: 429–30PubMedGoogle Scholar
  15. 15.
    Prichard PJ, Walt RP, Kitchingman GK, et al. Oral pheny-toin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543–5PubMedCrossRefGoogle Scholar
  16. 16.
    Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–41Google Scholar
  17. 17.
    Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 1990; 12: 329–33PubMedCrossRefGoogle Scholar
  18. 18.
    Ahmad S. Omeprazole—warfarin interaction. South Med J 1991; 84: 674–5PubMedGoogle Scholar
  19. 19.
    Suftin T, Balmer K, Bostrom H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176–84CrossRefGoogle Scholar
  20. 20.
    de Hoon JN, Thujssen HH, Beysens AJ, et al. No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997; 44: 399–401PubMedCrossRefGoogle Scholar
  21. 21.
    Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509–12PubMedCrossRefGoogle Scholar
  22. 22.
    Bottiger Y, Tybring G, Gotharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62: 384–91PubMedCrossRefGoogle Scholar
  23. 23.
    Furuta T, Ohashi K, Kobayashi K, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999; 66: 265–74PubMedCrossRefGoogle Scholar
  24. 24.
    Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after single oral dose. Br J Clin Pharmacol 1991; 32: 569–72PubMedCrossRefGoogle Scholar
  25. 25.
    Soons PA, van der Berg G, Danhof M, et al. Influence of single- and multiple-dose omeprazole treatment on nife-dipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992; 42: 319–24PubMedCrossRefGoogle Scholar
  26. 26.
    Lefevre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458–63CrossRefGoogle Scholar
  27. 27.
    Ko JW, Jang U, Shin JG, et al. Theophyline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Clin Pharmacol Ther 1999; 65: 606–14PubMedCrossRefGoogle Scholar
  28. 28.
    Karol MD, Locke CS, Cavanaugh JH. Lack of pharmaco-kinetic interaction between lansoprazole and intravenously administered phenytoin. J Clin Pharmacol 1999; 39: 1283–9PubMedCrossRefGoogle Scholar
  29. 29.
    Braeckman RA, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on warfarin pharmacokinetics and anti-coagulation effect in healthy subjects. Pharmacol Res 1991; 8 Suppl 10: s295Google Scholar
  30. 30.
    Gerson LB, Triadafilopoulos. Proton pump inhibitors and their drug interactions: an evidence-base approach. Eur J Gastroenterol Hepatol 2001; 13: 611–6PubMedCrossRefGoogle Scholar
  31. 31.
    Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523–37PubMedCrossRefGoogle Scholar
  32. 32.
    Humphries T. A review on the drug—drug interaction potential of rabeprazole sodium based on CYP-450 interference or absorption effects. Digestion 1998; 59 Suppl 3: 76Google Scholar
  33. 33.
    Humphries TJ, Nardi RV, Spera AC, et al. Coadministration of rabeprazole sodium (E-3810) and ketoconazole results in a predictable interaction with ketoconazole. Gastroenterology 1996; 110: A138Google Scholar
  34. 34.
    Labenz J, Petersen KU, Rösch W, et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003; 17: 1015–9PubMedCrossRefGoogle Scholar
  35. 35.
    Keane WF, Swan SK, Grimes I, et al. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol 1999; 39: 927–33PubMedCrossRefGoogle Scholar
  36. 36.
    Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34: 185–94PubMedGoogle Scholar
  37. 37.
    Flouvat B, Delhotal-Landers B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467–9PubMedCrossRefGoogle Scholar
  38. 38.
    Whitaker M. Proton pump inhibitors in the elderly population. Eur J Gastroenterol Hepatol 2002; 14 Suppl 1: S5–9PubMedCrossRefGoogle Scholar
  39. 39.
    Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharma-cokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001; 40: 145–50PubMedCrossRefGoogle Scholar
  40. 40.
    Irl C, Kipferler P, Hasford J. Drug use assessment and evaluation in pregnancy — the Pegasus project. Pharma-coepidemiol Drug Saf 1997; 6 Suppl 3: S37–42CrossRefGoogle Scholar
  41. 41.
    Capell MS, García A. Gastric and duodenal ulcers during pregnancy. Gastroenterol Clin North Am 1998; 27: 169–95CrossRefGoogle Scholar
  42. 42.
    Charan M, Katz PO. Gastroesophageal reflux disease in pregnancy. Curr Treat Options Gastroenterol 2001; 4: 73–81PubMedCrossRefGoogle Scholar
  43. 43.
    Ching MS, Morgan DJ, Mihaly GW, et al. Placental transfer of omeprazole in maternal and fetal sheep. Dev Pharmacol Ther 1986; 9: 323–31PubMedGoogle Scholar
  44. 44.
    Nifkar S, Abdollahi M, Moretti ME, et al. Use of proton pump inhibitors during pregnancy and rates of major malformations. A meta-analysis. Dig Dis Sci 2002; 47: 1526–9Google Scholar
  45. 45.
    Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50: 366–72PubMedCrossRefGoogle Scholar
  46. 46.
    García Rodriguez LA, Mannino S, Wallander MA, et al. A cohort study of the ocular safety of anti-ulcer drugs. Br J Clin Pharmacol 1996; 42: 213–6PubMedCrossRefGoogle Scholar
  47. 47.
    Freston JW. Clinical significance of hypergasrinemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51 Suppl 1: 102–14PubMedCrossRefGoogle Scholar
  48. 48.
    Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci 1991; 36: 552–7Google Scholar
  49. 49.
    Mattsson H, Havu N, Bräutigam J, et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterology 1991; 100: 311–9PubMedGoogle Scholar
  50. 50.
    Solcia E, Fiocca R, Villani L, et al. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995; 19 Suppl 1: S1–7PubMedCrossRefGoogle Scholar
  51. 51.
    Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and H.pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018–22PubMedCrossRefGoogle Scholar
  52. 52.
    Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology 1999; 117: 319–26Google Scholar
  53. 53.
    Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661–9PubMedCrossRefGoogle Scholar
  54. 54.
    Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 1994; 35: 455–60PubMedCrossRefGoogle Scholar
  55. 55.
    García Rodriguez LA, Ruizgomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk. Epidemiology 1997; 8: 571–4PubMedCrossRefGoogle Scholar
  56. 56.
    Allen RH, Seetharam B, Podell E, et al. Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. J Clin Invest 1978; 61: 47–54PubMedCrossRefGoogle Scholar
  57. 57.
    Marcuard SP, Albernarz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994; 120: 211–5PubMedGoogle Scholar
  58. 58.
    Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003; 5: 25–40PubMedGoogle Scholar
  59. 59.
    Henry D, Brent P, White I, et al. Propanolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33: 369–73PubMedCrossRefGoogle Scholar
  60. 60.
    Dilger K, Zheng Z, Klotz U. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophyline. Br J Clin Pharmacol 1999; 48: 438–44PubMedCrossRefGoogle Scholar
  61. 61.
    Ching MS, Elliott SL, Stead CK, et al. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Aliment Pharmacol Ther 1991; 5: 523–31PubMedCrossRefGoogle Scholar
  62. 62.
    Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 1993; 35: 156–60PubMedGoogle Scholar
  63. 63.
    Itagaki F, Homma M, Yuzawa K, et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Trans Proc 2002; 34: 2777–8CrossRefGoogle Scholar
  64. 64.
    Gugler R, Hartmann M, Rudi J, et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 1996; 42: 249–52PubMedCrossRefGoogle Scholar
  65. 65.
    Middle MW, Müller FO, Schall R, et al. No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 1996; 34 Suppl 1: S72–5PubMedGoogle Scholar
  66. 66.
    Duursema L, Müller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995; 39: 700–3PubMedCrossRefGoogle Scholar
  67. 67.
    Schulz HU, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophyline in man. Int J Clin Pharmacol Ther 1996; 34 Suppl 1: S51–7PubMedGoogle Scholar
  68. 68.
    Bliesath H, Huber R, Steinijans VW, et al. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 1996; 34: 51–5PubMedGoogle Scholar
  69. 69.
    Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxilation. Clin Pharmacol Ther 1995; 58: 155–64PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Gastroenterology Department‘Ramón y Cajal’ HospitalMadridSpain

Personalised recommendations